Cargando…
Changing therapy from Glivec(® )to a "copy" imatinib results in a worsening of chronic myeloid leukemia disease status: two case reports
INTRODUCTION: Imatinib mesylate (Glivec(®)/Gleevec(®)) is the standard first-line therapy for the treatment of chronic myeloid leukemia due to its high hematologic, cytogenetic, and molecular response rates and favorable long-term safety profile. A copy version of imatinib is currently available in...
| Autores principales: | , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2009
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2803998/ https://www.ncbi.nlm.nih.gov/pubmed/20062598 http://dx.doi.org/10.1186/1757-1626-2-9342 |